该研究也支持以前关于罗非考昔（Vioxx）与心血管副作用相关的结论。
The findings also support prior research linking rofecoxib (Vioxx) with adverse cardiovascular effects.
罗非考昔能显著增加腹泻和降低便秘、疲劳、发热、体重减轻、疼痛和止痛剂消耗发生率。
Rofecoxib significantly increased the incidence of diarrhoea and decreased constipation, fatigue, fever, weight loss, and pain, and analgesic consumption.
罗非考昔可提高患者治疗反应率和数个生活质量项目，包括疼痛相关项目和总的生活质量。
Rofecoxib improved response rate and several quality-of-life items, including pain-related items and global quality of life.
1998年默克把罗非考昔推向市场时，曾吹嘘该药是阿司匹林等止痛药更加安全的替代药品。
Vioxx was touted as a safer alternative to painkillers such as aspirin when it was introduced in 1998.
罗非考昔使用者的心血管事件发生率最高，而萘普生的发生率最低，甚至比不应用药物的人还要低。
Rofecoxib users had the highest event rates, while naproxen users had the lowest, even lower than non users.
对不同的非甾体抗炎药的评估后进一步分析显示，在整个患者亚群中仅仅罗非考昔和布洛芬增加了心血管事件发生的风险。
Further analysis showed that of the various NSAIDs evaluated, only rofecoxib and ibuprofen increased the risk of cardiovascular events across patient subgroups.
对不同的非甾体抗炎药的评估后进一步分析显示，在整个患者亚群中仅仅罗非考昔和布洛芬增加了心血管事件发生的风险。
Further analysis showed that of the various NSAIDs evaluated, only rofecoxib and ibuprofen increased the risk of cardiovascular events across patient subgroups.
应用推荐